

Acarix Q2 2024 - Soft revenues but keeps progressing

Redeye updates its view on Acarix following its Q2 2024 report. While revenues increase both y/y and q/q the ramp-up is taking longer than we were hoping for. On the other hand, progress is being made on several fronts, and the potential in the business case remains high. We trim our base case.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Acarix Q2 2024 - Soft revenues but keeps progressing